Clinical Trials Logo

Filter by:
  • Terminated  
  • « Prev · Page [53]
NCT ID: NCT00124748 Terminated - Clinical trials for Leukemia, Myeloid, Chronic Phase

Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)

TOPS
Start date: June 2005
Phase: Phase 3
Study type: Interventional

This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.

NCT ID: NCT00102791 Terminated - Sickle Cell Disease Clinical Trials

A Stratified Sickle Event Randomized Trial (ASSERT)

ASSERT
Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.

NCT ID: NCT00089804 Terminated - Lupus Nephritis Clinical Trials

Study of LJP 394 in Lupus Patients With History of Renal Disease

ASPEN
Start date: October 2004
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether abetimus sodium is more effective than placebo in delaying time to renal flare in SLE patients with a history of renal disease.

NCT ID: NCT00057382 Terminated - Clinical trials for Hepatocellular Carcinoma

T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients

Start date: March 2003
Phase: Phase 2/Phase 3
Study type: Interventional

This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer. A total of 750 subjects will be enrolled in this study.